Top

Published in:

01-12-2008 | Epidemiology

Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer

Authors: Joanne Kotsopoulos, William W. Zhang, Shiyu Zhang, David McCready, Maureen Trudeau, Phil Zhang, Ping Sun, Steven A. Narod

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Abstract

Background An accumulating body of evidence suggests that there is an inverse relationship between the intake of folate (a water-soluble B-vitamin) and the risk of developing breast cancer. Individual variation in the genes involved in the transport of folate, or its metabolism, may affect risk, or may modify the association between folate and breast cancer risk. Methods We performed a case-control study to evaluate the association between common polymorphisms in six folate-related genes and the risk of breast cancer in 1,009 breast cancer patients and 907 healthy controls. Study subjects were genotyped for eight single nucleotide polymorphisms (SNPs) in these six genes. Results We observed no association between the MTHFR, RFC, MS and MTRR genotypes and the risk of breast cancer. Conclusion These data do not support the hypothesis that genetic variation in genes involved in the metabolism of folate are implicated in the etiology of breast cancer.

Kim YI (1999) Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem 10(2):66–88PubMedCrossRef

Wagner C (1995) Biochemical role of folate in cellular metabolism. In: Bailey LB (ed) Folate in health and disease. Marcel Dekker Inc, New York, pp 23–42

Selhub J, Miller JW (1992) The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55(1):131–138PubMed

Baylin SB et al (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196PubMedCrossRef

Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21(2):163–167PubMedCrossRef

Duthie SJ (1999) Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull 55(3):578–592PubMedCrossRef

Kim YI (2004) Folate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies. Environ Mol Mutagen 44(1):10–25PubMedCrossRef

Zhang SM (2004) Role of vitamins in the risk, prevention, and treatment of breast cancer. Curr Opin Obstet Gynecol 16(1):19–25PubMedCrossRef

Eichholzer M et al (2001) Folate and the risk of colorectal, breast and cervix cancer: the epidemiological evidence. Swiss Med Wkly 131(37–38):539–549PubMed

10.

Lewis SJ et al (2006) Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. J Natl Cancer Inst 98(22):1607–1622PubMedCrossRef

11.

Zhang S et al (1999) A prospective study of folate intake and the risk of breast cancer. Jama 281(17):1632–1637PubMedCrossRef

12.

Rohan TE et al (2000) Dietary folate consumption and breast cancer risk. J Natl Cancer Inst 92(3):266–269PubMedCrossRef

13.

Sellers TA et al (2001) Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology 12(4):420–428PubMedCrossRef

14.

Shrubsole MJ et al (2001) Dietary folate intake and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Res 61(19):7136–7141PubMed

15.

Sharp L, Little J (2004) Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 159(5):423–443PubMedCrossRef

16.

Ulrich CM, Robien K, Sparks R (2002) Pharmacogenetics and folate metabolism – a promising direction. Pharmacogenomics 3(3):299–313PubMedCrossRef

17.

Justenhoven C et al (2005) One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany. Cancer Epidemiol Biomarkers Prev 14(12):3015–3018PubMedCrossRef

18.

Zhai X et al (2006) Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis. BMC Cancer 6:138PubMedCrossRef

19.

Xu WH et al (2007) Dietary folate intake, MTHFR genetic polymorphisms, and the risk of endometrial cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 16(2):281–287PubMedCrossRef

20.

Zintzaras E (2006) Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a meta-analysis. Clin Genet 69(4):327–336PubMedCrossRef

21.

Mason JB, Rosenberg IH (1994) Intestinal absorption of folate. In: Johnson LR (ed) Physiology of the gastrointestinal tract. Raven, New York

22.

Shane B (1995) Folate chemistry and metabolism. In: Bailey LB (ed) Folate in health and disease. Marcel Dekker Inc, New York, pp 1–22

23.

Chango A et al (2000) A polymorphism (80G→A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 70(4):310–315PubMedCrossRef

24.

Schirch L, Peterson D (1980) Purification and properties of mitochondrial serine hydroxymethyltransferase. J Biol Chem 255(16):7801–7806PubMed

25.

Schirch L (1982) Serine hydroxymethyltransferase. Adv Enzymol Relat Areas Mol Biol 53:83–112PubMedCrossRef

26.

Heil SG et al (2001) Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol Genet Metab 73(2):164–172PubMedCrossRef

27.

Frosst P et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111–113PubMedCrossRef

28.

Weisberg I et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64(3):169–172PubMedCrossRef

29.

Sharp L et al (2002) Folate and breast cancer: the role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR). Cancer Lett 181(1):65–71PubMedCrossRef

30.

Le Marchand L et al (2004) MTHFR polymorphisms, diet, HRT, and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 13(12):2071–2077PubMed

31.

Campbell IG et al (2002) Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 4(6):R14PubMedCrossRef

32.

Gershoni-Baruch R et al (2000) Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer 36(18):2313–2316PubMedCrossRef

33.

Rady PL et al (2002) Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 107(2):162–168PubMedCrossRef

34.

Leclerc D et al (1996) Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 5(12):1867–1874PubMedCrossRef

35.

Harmon DL et al (1999) Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 17(4):298–309PubMedCrossRef

36.

Pufulete M et al (2005) Influence of folate status on genomic DNA methylation in colonic mucosa of subjects without colorectal adenoma or cancer. Br J Cancer 92(5):838–842PubMedCrossRef

37.

Wilson A et al (1999) A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 67(4):317–323PubMedCrossRef

38.

Gaughan DJ et al (2001) The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 157(2):451–456PubMedCrossRef

39.

Geisel J et al (2001) Genetic defects as important factors for moderate hyperhomocysteinemia. Clin Chem Lab Med 39(8):698–704PubMedCrossRef

40.

O’Leary VB et al (2002) MTRR and MTHFR polymorphism: link to Down syndrome? Am J Med Genet 107(2):151–155PubMedCrossRef

41.

Kraus JP et al (1998) The human cystathionine beta-synthase (CBS) gene: complete sequence, alternative splicing, and polymorphisms. Genomics 52(3):312–324PubMedCrossRef

42.

Shen M et al (2005) Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung Cancer 49(3):299–309PubMedCrossRef

43.

Shrubsole MJ et al (2004) MTHFR polymorphisms, dietary folate intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 13(2):190–196PubMedCrossRef

Title: Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer
Authors: Joanne Kotsopoulos
William W. Zhang
Shiyu Zhang
David McCready
Maureen Trudeau
Phil Zhang
Ping Sun
Steven A. Narod
Publication date: 01-12-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-9895-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus

Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases

Paget’s disease of the breast: the experience of the European institute of oncology and review of the literature

The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation

The MSKCC nomogram for prediction the likelihood of non-sentinel node involvement in a German breast cancer population

HER2 in well differentiated breast cancer: is testing necessary?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer